Document is current
Any future updates will be listed below
-
Authors
Breukers, Sabine E.
Traets, Joleen J. H.
van Dijk, Stan W. https://orcid.org/0009-0006-3161-5659
Ostos, Mercedes Machuca
Fraterman, Itske https://orcid.org/0000-0001-7974-8422
Crommelin, Robert D.
van der Hulst, Hedda https://orcid.org/0000-0002-6932-9838
Qiao, Xiaohang https://orcid.org/0000-0002-8690-4179
Boere, Thomas
van de Poll-Franse, Lonneke V. https://orcid.org/0000-0003-0413-6872
Retèl, Valesca
van der Noort, Vincent https://orcid.org/0000-0002-4910-4535
Vos, Joris L. https://orcid.org/0000-0002-8318-5455
Toppenberg, Alexandra G. L.
van der Heijden, Martijn
Missale, Francesco
Balm, Fons
van den Brekel, Michiel https://orcid.org/0000-0002-6338-6743
Dirven, Richard
Karakullukcu, M. Baris
Karssemakers, Luc
Klop, W. Martin C.
Lohuis, Peter J.F.M
Schreuder, Willem H.
Smeele, Ludi E.
van der Velden, Lilly-Ann
Plasmeijer, Elsemieke
Smit, Laura A.
de Boer, Jan Paul
Navran, Arash
Westerink, Bram https://orcid.org/0009-0003-7483-8260
de Koekkoek-Doll, Petra K.
Castelijns, Jonas
Wondergem, Maurits
Vogel, Wouter V.
Kuijpers, Anke
van Houdt, Winan J.
Onderwater, Suzanne
Maas-Bannink, Esther
Cornelissen, Sten
Broeks, Annegien
Tijink, Bernard M.
Devriese, Lot A.
de Bree, Remco
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
Thommen, Daniela S. https://orcid.org/0000-0002-7431-2854
Haanen, John B.A.G. https://orcid.org/0000-0001-5884-7704
Zuur, Charlotte L. https://orcid.org/0000-0002-1777-012X
-
Funding
Funding for this research was provided by:
Brystol-Myer Squibb Riki Foundation
funding from BMS, Novartis, and Nanostring
- License Information
-
More Information
Article History
Received: 9 December 2024
Accepted: 5 August 2025
First Online: 8 October 2025
Competing interests
: C.L.Z. reports receiving institutional research financial support from BMS to fund the present trial. J.B.A.G.H. reports the following, all outside the submitted work: institutional honoraria for advisory roles for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures and Vaximm; stock option ownership of Neogene Therapeutics; and institutional research funding from Amgen, BioNTech, BMS, MSD and Novartis. L.A.D. reports payments to her institution and a speaker’s fee from Merck. T.N.S. is a venture partner at Third Rock Ventures; an advisor to and stockholder in Allogene Therapeutics, Merus and Scenic Biotech; and founder of, advisor to and stockholder in Asher Bio, Cell Control, Neogene Therapeutics and Polar Therapeutics, all outside the current work. D.S.T. reports research grants from Asher Biotherapeutics and Bristol-Myers Squibb outside the submitted work. M.v.d.B. reports that the Department of Head and Neck Oncology and Surgery receives a research grant from ATOS Medical. C.U.B holds or has held several advisory roles (all paid to the institute except for TRV) for BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures, Senya and Hexal/Sandoz. Furthermore, he received research funding (all paid to the institute) from BMS, Novartis, NanoString, 4SC and Senya Therapeutics. He co-founded Flindr Therapeutics to develop TNF sensitizers to clinical application; he holds a very low percentage of stockownership and cannot vote. He has submitted the following patents (filed in The Netherlands, all owned by the institute; WO, worldwide; US, USA; EP, Europe): WO 2021/177822 A1 (pending), US 2023/0114276 A1 (pending), EP 4114450 A1 (pending), WO 2023/022596 A1 (pending), US (submitted not published yet) and EP 4387683 A1 (pending). The remaining authors declare no competing interests.
